Safety and tolerability
nausea, TEAEs, vomiting, anemia, 1.5%).Dose, upper abdominal pain, decreased appetite, TEAE
ADVERSE EVENT, ANEMIA
There was a similar incidence of TEAEs between treatment arms; 91.5% of patients receiving pamiparib and 93.8% of patients receiving placebo experienced ≥1 TEAE (Table Summary of TEAE incidence (safety analysis set).Abbreviations: TEAE, treatment‐emergent adverse event; TRAE, treatment‐related adverse event.TEAEs reported in ≥10% of patients in either arm (safety analysis set).Abbreviation: TEAE, treatment‐emergent adverse event.The proportions of patients experiencing ≥1 TRAE were 77.5% and 52.3% in the pamiparib and placebo arms, respectively. The most common TRAEs were anemia (pamiparib 22.5%, placebo 10.8%), nausea (pamiparib 23.9%, placebo 6.2%), and decreased appetite (pamiparib 18.3%, placebo 1.5%).Dose modifications due to a TEAE occurred in 28.2% and 13.8% of patients in the pamiparib and placebo arms, respectively. The most common TEAEs leading to dose modification were anemia (7.0%), vomiting (5.6%) and upper abdominal pain (4.2%) in the pamiparib arm, and anemia (3.1%) in the placebo arm.Eight patients (11.3%) in the pamiparib arm and 2 patients (3.1%) in the placebo arm experienced ≥1 TEAE leading to treatment discontinuation (Table 